HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
(d)
On March 28, 2019, the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”) appointed John L. Lubniewski as a member of the Board, effective immediately. Mr. Lubniewski currently serves as the Company’s President and Chief Executive Officer.
(e)
Employment Agreement with Timothy B. Johnson
On March 31, 2019, in connection with the transition of Timothy B. Johnson from the role of Chief Executive Officer to Executive Chairman, the Company entered into a new employment agreement with Mr. Johnson. to the new agreement, which replaces Mr. Johnson’s prior agreement with the Company dated December 24, 2014, Mr. Johnson will receive an annual base salary of $100,000 for his service as Executive Chairman. Mr. Johnson will remain eligible for an annual performance bonus for his service as Chief Executive Officer, prorated for the period during which he served in that role from January 1, 2019 to March 31, 2019. As Executive Chairman, Mr. Johnson will also be eligible to receive discretionary bonuses as determined by the Board in its sole discretion.
Employment Agreement with John L. Lubniewski
On April 1, 2019, in connection with the appointment of Mr. Lubniewski as the Company’s Chief Executive Officer, the Company entered into a new employment agreement with Mr. Lubniewski. The new agreement, which replaces Mr.Lubniewski’s prior agreement with the Company dated December 18, 2014, memorializes the base salary and annual target bonus opportunity previously approved by the Board in January 2019 in connection with Mr. Lubniewski’s promotion to Chief Executive Officer, as described in the Company’s Current Report on Form8‑K filed with the Securities and Exchange Commission on January 30, 2019.
The foregoing descriptions are not complete and are qualified in their entirety by reference to the full text of the respective employment agreements, copies of which are attached to this report as Exhibits 10.1 and 10.2.
Item 5.02 Financial Statements and Exhibits.
(d)Exhibits.
HTG MOLECULAR DIAGNOSTICS, INC Exhibit
EX-10.1 2 htgm-ex101_7.htm EX-10.1 htgm-ex101_7.htm Exhibit 10.1 March 31,…
To view the full exhibit click here
About HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.